Scarica l'app Stockscreener
86.82
0.39%
0.34
Dopo l'orario di chiusura:
85.91
-0.91
-1.05%
Precedente Chiudi:
$86.48
Aprire:
$87.54
Volume 24 ore:
377.70K
Relative Volume:
0.41
Capitalizzazione di mercato:
$4.75B
Reddito:
$1.34M
Utile/perdita netta:
$-173.66M
Rapporto P/E:
-20.98
EPS:
-4.1385
Flusso di cassa netto:
$-130.49M
1 W Prestazione:
+1.34%
1M Prestazione:
-0.65%
6M Prestazione:
+97.18%
1 anno Prestazione:
+371.21%
Intervallo 1D:
$85.43
$89.23
Intervallo di 1 settimana:
$85.43
$91.19
Portata 52W:
$16.64
$96.50
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
86.82 | 4.73B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Biotech Dianthus to meet investors at Jefferies and Goldman events - Stock Titan
Dianthus (DNTH) director receives 6,090 options vesting by 2027 - Stock Titan
Dianthus Therapeutics (DNTH) director receives grant of 6,090 stock options - Stock Titan
Director at Dianthus Therapeutics (DNTH) granted 6,090 stock options - Stock Titan
Dianthus (DNTH) director Jonathan Violin receives grant of 6,090 stock options - Stock Titan
Director Paula Soteropoulos gets 6,090 DNTH options in new award - Stock Titan
Dianthus (NASDAQ: DNTH) investors approve board, pay and auditor - Stock Titan
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish - AOL.com
Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital Raise - Yahoo Finance
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - sharewise.com
Dianthus Therapeutics CFO sold 8,224 shares worth $739,000. - Pluang
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - The Motley Fool
RA Capital group reports 2,611,733 Dianthus shares (DNTH) - Stock Titan
Point72 reports 643,599 shares (1.2%) in Dianthus Therapeutics (DNTH) - Stock Titan
Sirenia Capital (DNTH) discloses 5.3% stake including 500K options - Stock Titan
Wellington group reports 4.77% stake in Dianthus (NASDAQ: DNTH) - Stock Titan
Tango Therapeutics is the best performing healthcare stock in March - MSN
Octagon entities disclose 1.95M-share stake in Dianthus Therapeutics (DNTH) - Stock Titan
Vanguard Group Inc. Increases Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $65.2 to $200 - Moomoo
TradingKey - TradingKey
Dianthus Therapeutics (DNTH) director exercises options, sells 599 shares under 10b5-1 plan - Stock Titan
Evercore Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $120 - Moomoo
UBS Group AG Acquires 469,547 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Brokerages - MarketBeat
Number of shareholders of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Number of shareholders of Dianthus Therapeutics, Inc. – SWB:87E - TradingView
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
Q2 EPS Forecast for Dianthus Therapeutics Raised by Analyst - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: 47.87% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Raymond James Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $110 - Moomoo
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $125 to $200 - Moomoo
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results - The Manila Times
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates - MSN
MSN Money - MSN
Dianthus Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q1 Revenue $463K, vs. FactSet Est of $404K - marketscreener.com
Dianthus Therapeutics Q1 net loss widens on higher expenses - TradingView
Dianthus Therapeutics (NASDAQ: DNTH) builds $1.1B cash to fund autoimmune pipeline - Stock Titan
Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dianthus got 20 responders before 40 patients in CIDP trial - Stock Titan
Dianthus (Nasdaq: DNTH) raises $719M, ends Q1 2026 with $1.2B cash - Stock Titan
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dianthus Therapeutics Inc Azioni (DNTH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Soteropoulos Paula | Director |
May 08 '26 |
Sale |
85.47 |
599 |
51,197 |
0 |
| Savitz Ryan | EVP, CFO & CBO |
Apr 09 '26 |
Option Exercise |
17.88 |
8,224 |
147,045 |
8,224 |
| Savitz Ryan | EVP, CFO & CBO |
Apr 09 '26 |
Sale |
89.84 |
8,224 |
738,844 |
0 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):